Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 47, Status: Authorised
-
Published:2019-10-10
Issue:
Volume:
Page:
-
ISSN:2643-4652
-
Container-title:Case Medical Research
-
language:en
-
Short-container-title:CMR
Subject
Applied Mathematics,General Mathematics
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rituximab bij auto-immune blaarziekten;Tijdschrift voor Geneeskunde;2023-10-26